Cannabis Science Announces Participation in Major U.S.-Africa Policy Forum in Washington, DC

IRVINE, CA--(Marketwired - Sep 11, 2017) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that its senior executives will participate in the Constituency for Africa's (CFA) 2017 Ronald H. Brown African Affairs Series. The Series will be held September 18th-22nd in Washington, DC.

For over 26 years, CFA has established itself as one of the leading, non-partisan organizations focused on educating and mobilizing the American public and the African Diaspora in the U.S. on U.S.-Africa policy. As a result, CFA has helped to increase the level of cooperation and coordination among a broad-based coalition of individuals and organizations committed to the progress, development, and empowerment of Africa and African people worldwide.

The highlight of CFA's annual initiatives is the Ronald H. Brown African Affairs Series. The theme of this year's series is Mobilizing the Diaspora in Support of the U.S.-Africa Agenda, and the series is being organized by CFA in cooperation with the African Union Mission to the United States. The purpose of the 2017 Series is to bring together stakeholders from the U.S., Africa, and the African Diaspora to assess the U.S. Administration's Africa policy, and to identify challenges and opportunities in a number of key areas, including African healthcare infrastructure. The expected outcomes of the Series will include policy recommendations for the U.S. Administration and the African Union.

Mr. Raymond C. Dabney, Cannabis Science's President, CEO, Co-founder, and Director, and Dr. Allen Herman, CBIS' Chief Medical Officer, will deliver remarks at CFA's African Healthcare Infrastructure Roundtable on Tuesday, September 19th, and participate in a bi-partisan, senior-level U.S.-Africa Policy Forum on Thursday, September 21st. "I look forward to Cannabis Science's participation in this year's Ronald H. Brown African Affairs Series. This Series provides our company with the opportunity to engage with key U.S. and African stakeholders in government, private sector, civil society, and academia. These potential partnerships will enable Cannabis Science to accelerate our African drug-development initiative, as well as to build on our current collaborations for research and multi-center clinical trials," stated Mr. Dabney.